期刊文献+

聚乳酸/羟基磷灰石微球的合成与性能 被引量:1

Synthesis and Performance of PLA/HA Microspheres
下载PDF
导出
摘要 以生物可降解高分子材料聚乳酸(PLA)为载体,羟基磷灰石(HA)为核心材料,采用溶剂蒸发法制备了聚乳酸/羟基磷灰石(PLA/HA)微球。在可确定因素固定下来后,在保证成球质量的基础上,分别通过调节乳化剂浓度和其它因素在一定范围内控制微球的平均粒径。通过正交实验摸索出制得粒径大小为200μm左右PLA/HA微球的最佳工艺方案:搅拌速度为500r.min-1,PLA浓度为0.08g.mL-1,PVA浓度为0.006g.mL-1,HA添加量为0.10g。扫描电镜(SEM)表明微球外观基本光滑圆整,但表面有少许小孔和凹槽;观察了PLA/HA微球在生理盐水中的降解行为,发现其降解速率低于纯聚乳酸;通过对微球释药率的研究发现其具有良好的缓释性能。 Polylactic acid/hydroxyapatite(PLA/HA) composite microspheres were prepared through O/W emulsion/solvent evaporation method by choosing PLA as carrier and HA as core materials.On the basis of ensuring the quality of produced particles,the concentration of emulsifier and other factors were adjusted in a certain range to control the average particle sizes of microspheres after the confirmable factors were fixed.The best crafts to synthesize PLA/HA microspheres with the diameters of about 200μm were found through orthogonal-designed experiment: stirring rate was 500r/min,concentration of PLA was 0.08g/mL,concentration of PVA was 0.006g/mL and adding amounts of HA was 0.10g.SEM showed that the appearance of microspheres was smooth and sphere,but there were some stomas and grooves on the surface;it was found that the degradation speed of PLA/HA microspheres was lower than pure PLA through observation of their degradation behavior in buffer solution;the microspheres having good drug-releasing properties was found by researching drug-releasing rate of PLA/HA microspheres.
出处 《化工技术与开发》 CAS 2010年第9期4-7,共4页 Technology & Development of Chemical Industry
基金 江苏省生态环境材料重点实验室重点学科建设开放基金(XKY2007015)
关键词 PLA/HA微球 合成 性能 正交设计 PLA/HA microspheres synthesize performance orthogonal-designed method
  • 相关文献

参考文献10

二级参考文献108

共引文献60

同被引文献18

  • 1Canalis E. Clinical Endocrinology & Metabolism, 2010, 95(4):1496-1506.
  • 2Blind E.Clinical Laboratory, 2008, 54(11):439-449.
  • 3Pleiner D J, Zwettler E, Paschalis E.Calcified Tissue International, 2009, 84(3):159-170.
  • 4Chen C, Koh A J, Datta N S.J Biol Chem, 2004, 279:29121-29129.
  • 5Devogelaer J P, Boutsen Y, Manicourt D H.Current Osteoporosis Report, 2010, 8(3):154-161.
  • 6Inoue D, Matsumoto T.Biomed Pharma-cother, 2000, 54:32s-41s.
  • 7Horwitz M J, Tedesco M B, Gundberg C.J Clin Endocrinol Metab, 2003, 88:569-575.
  • 8Stewrat A F, Cain R L, Burr D B.J Bone Miner Res, 2000, 15(8):1517-1525.
  • 9Jiang G, Matsumoto H, FujⅡ A.J Dent Res, 2007, 86:52-57.
  • 10Yang J, Farnell D, Devlin H.J Dent Res, 2005, 33:123-129.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部